Maze Therapeutics
Maze Therapeutics’ MZE782 Shows Strong Phase 1 Data, Targets PKU and CKD
Maze Therapeutics’ SLC6A19 inhibitor MZE782 showed >40-fold phenylalanine excretion in Phase 1, advancing toward Phase 2 trials in PKU and CKD. The data position MZE782 as a potential best-in-class therapy for PKU and first-in-class option for CKD, directly challenging Jnana’s JNT-517.